



BLOOM BURTON  
AWARD GALA

AWARD GALA PROGRAM

# Contents

02

**WELCOME LETTER**  
Brian Bloom and Jolyon Burton

04

**MESSAGE FROM THE PRIME MINISTER**  
Justin Trudeau

06

**MESSAGE FROM THE PREMIER**  
Doug Ford

08

**MESSAGE FROM THE MAYOR**  
John Tory

12

**FINALIST PROFILES**  
Clarissa Desjardins | Richard Glickman | Ali Tehrani

18

**JUDGING PANEL**  
Karen Bernstein | Cecilia Gonzalo | Carl Gordon  
Dennis Purcell | Melinda Richter | Avik Roy  
Mayukh Sukhatme

# 02

# Welcome

Thank you for attending the Bloom Burton Award Gala.

We are delighted that you are here to celebrate leaders in the Canadian healthcare sector.

The Bloom Burton Award Gala seeks to honour an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker - anyone - who has made the greatest impact in Canada's innovative healthcare industry. It's time to celebrate those who advance medical science, attract and provide risk capital, launch new products and companies on the world stage or announce significant monetization events.

The public-at-large nominated the candidates for this award and our international judging panel has narrowed and selected three finalists who deserve our recognition: Clarissa Desjardins of Clementia Pharmaceuticals, Richard Glickman of Aurinia Pharmaceuticals and Ali Tehrani of Zymeworks.

Let's raise our glasses and toast their enormous achievements!



Brian Bloom



Jolyon Burton

# Anthony Giovinazzo

## Recipient of the 2017 Bloom Burton Award

It is with great pleasure that I write to you the finalists, colleagues, family members and friends attending the second annual Bloom Burton Award Gala.

As the recipient of the first award, I am grateful and elated that Bloom Burton created this very important recognition for the Canadian men and women that toil day in and out for many years, to ultimately make a difference in patients' lives around the world.

Brian Bloom and Jolyon Burton, themselves espouse the very characteristics of what it takes to become a successful person in this field. Perseverance, embracing innovation, stamina, passionate belief and taking disparate pieces of information and stitching them together to arbitrage and exploit an opportunity for the betterment of mankind.

I am excited for the three finalists tonight. It is a significant achievement to have been a nominee and to be selected as a finalist. It demonstrates the profound respect that the nominators and the judges hold for you and your achievements. In addition, you are now, along with my two co-finalists and I from 2017, members of a club that will grow in size and gravitas, to continue to lead, champion and mentor this critical innovation segment of the Canadian economy.

To the ultimate winner, congratulations. The Bloom Burton Award Gala truly is the "Oscars" of the Canadian life sciences ecosystem. It is exciting and rewarding. What you realize as a finalist is that all the finalists deserve to be the winner. The event is full of great background stories through the videos and excitement leading up to the final announcement.

Enjoy the evening, it is well deserved!

**Anthony J. Giovinazzo**

Chairman & CEO

Red Granite Merchant Banking & Advisory

Recipient of the Inaugural Bloom Burton Award



PRIME MINISTER · PREMIER MINISTRE



The Rt. Hon. Justin P.J. Trudeau, P.C., M.P.  
Prime Minister of Canada



PRIME MINISTER • PREMIER MINISTRE

September 27, 2018

Dear Friends:

I am pleased to extend my warmest greetings to everyone attending the 2018 Bloom Burton Award Gala.

The Bloom Burton Award recognizes scientists and entrepreneurs who have made significant contributions to the Canadian healthcare sector. I join everyone in attendance this evening in congratulating this year's finalists, Dr. Clarissa Desjardins, Dr. Richard Glickman, and Dr. Ali Tehrani. Your accomplishments make you most deserving of this special recognition.

I would also like to thank the organizers of tonight's gala for fostering innovation in the healthcare industry.

Please accept my best wishes for an enjoyable evening and continued success.

Sincerely,

The Rt. Hon. Justin P.J. Trudeau, P.C., M.P.  
Prime Minister of Canada



Premier of Ontario - Premier ministre de l'Ontario



Doug Ford  
Premier of the Province of Ontario



**Premier of Ontario - Premier ministre de l'Ontario**

September 27, 2018

### **A MESSAGE FROM PREMIER DOUG FORD**

I'm pleased to extend greetings to everyone taking part in the annual Bloom Burton Award Gala.

I applaud the people at Bloom Burton & Co. for organizing this terrific event, and I want to thank everyone who helped to make it a success. You can all be proud of your dedication to promoting and celebrating excellence in the Canadian health care industry.

I also want to recognize all those being honoured this evening. Congratulations on your significant contributions. I wish you continued success.

I hope you all have an enjoyable evening.

A handwritten signature in blue ink that reads "Doug Ford".

**Doug Ford**  
**Premier**



John Tory  
Mayor of Toronto



### **Message from the Mayor**


It is my pleasure to extend greetings and a warm welcome to everyone attending the Bloom Burton Award Gala.

I would like to congratulate this year's award finalists who are innovators in the healthcare field and are being honoured for the significant contributions they have made to the Canadian healthcare sector.

The City of Toronto is proud of organizations and individuals that are committed to making a difference and recognizes their contributions to the economic and social well-being of our communities. Their tremendous efforts and talents impact the lives of many and make our city better.

On behalf of Toronto City Council, I thank the organizers and wish everyone an informative and enjoyable event.

Yours truly,



John Tory  
Mayor of Toronto

OFFICE OF THE MAYOR  
100 QUEEN STREET WEST, TORONTO, ONTARIO M5H 2N2

# 10

## Bloom Burton Award Gala

Bestowed annually, the Bloom Burton Award honours an individual scientist, inventor, executive, entrepreneur, industry leader, or policy maker who made the greatest contribution to Canada's innovative healthcare industry in the previous year.

Nominees for this year's award were accepted from the biotechnology, pharmaceutical, medical device, diagnostic/imaging, research instrumentation, consumer health, services and healthcare IT sectors, and equal consideration was given to contributions across all stages of development - from discovery to commercial end markets.

The Bloom Burton Award winner will be chosen from an esteemed panel of judges, all of whom are respected international leaders in healthcare investment, entrepreneurship and journalism.

# 2018

---

# Finalists

Our three finalists, Clarissa Desjardins, Richard Glickman and Ali Tehrani are being celebrated for their incredible contributions to the Canadian healthcare sector.

Each of the finalists will receive a \$25,000 cash prize, and a single winner will have the honour of being the 2018 Bloom Burton Award recipient.



Clarissa Desjardins  
Clementia Pharmaceuticals



Richard Glickman  
Aurinia Pharmaceuticals



Ali Tehrani  
Zymeworks

## 2017 HIGHLIGHTS

Clementia Pharmaceuticals successfully completed its IPO on Nasdaq and subsequently raised \$138 million dollars which will provide the company with enough funds for several years of operations.



# CLARISSA DESJARDINS

## Founder and CEO, Clementia Pharmaceuticals

Dr. Clarissa Desjardins founded Clementia in 2011 and has served as the company's chief executive officer since then. Prior to Clementia, she was CEO at the Centre d'excellence en médecine personnalisée (CEPMED), a Montreal-based federally and privately funded non-profit enterprise created to promote personalized medicine.

Dr. Desjardins is an award-winning entrepreneur with more than 18 years of biotechnology experience. She has founded three successful biotech companies, leading all aspects of company creation including conception and financing. She founded Advanced Bioconcept, a research reagent and diagnostics company sold to NEN Life Sciences (Perkin Elmer) in 1998. Dr. Desjardins also co-founded Caprion Pharmaceuticals, a biotechnology company focused on proteomic biomarker discovery and drug development, where she was executive vice-president of corporate development.

She received the BRIO award for outstanding contributions to the biotechnology industry from the Quebec Biotechnology Association and was named one of the top young Canadians likely to influence the future by the Globe and Mail. Dr. Desjardins has been a board member of numerous companies, including the scientific advisory council of the Canadian Academy of Sciences. Dr. Desjardins earned a doctorate in neurology and neurosurgery from McGill University's Faculty of Medicine and was a Medical Research Council postdoctoral fellow at the Douglas Hospital Research Centre.

# RICHARD GLICKMAN

## Co-founder and CEO, Aurinia Pharmaceuticals

Dr. Richard Glickman presently serves as the CEO and Chairman of the Board of Aurinia Pharmaceuticals. In addition to being a Founder of the company, he previously served as the Interim Executive Chairman of the Company for the period September 20, 2013 to February 28, 2014 and as Acting Interim CEO for the period October 22, 2013 to November 5, 2013.

He was a co-founder, Chairman and CEO of Aspreva Pharmaceuticals (“Aspreva”), playing an integral role in the development and establishment of CellCept®, or MMF, as the current standard of care for lupus nephritis. Aspreva Pharmaceuticals was acquired by Swiss pharmaceutical company Galenica for nearly \$1B in 2008. He currently serves as founding Chairman of Essa Pharmaceuticals Inc., Chairman of the Board of Engene Corporation and a Director of Cardiome Pharma. He is also a Partner at Lumira Capital, one of Canada’s most successful healthcare focused venture capital firms. Dr. Glickman has served on numerous biotechnology and community boards, including member of the federal government’s National Biotechnology Advisory Committee, Director of the Canadian Genetic Disease Network, Chairman of Life Sciences B.C. and a member of the British Columbia Innovation Council. Dr. Glickman is the recipient of numerous awards including the Ernst and Young Entrepreneur of the Year, a recipient of both BC and Canada’s Top 40 under 40 award, the BC Lifesciences Leadership Award and the Corporate Leadership Award from the Lupus Foundation of America (LFA).



---

## **2017 HIGHLIGHTS**

Aurinia Pharmaceuticals announced Voclosporin, its lead candidate for the treatment of Lupus Nephritis, had met all 48-week remission endpoints and achieved the highest completion rate of any global lupus nephritis study. The company also raised \$170 million dollars, the largest follow-on offering of any Canadian biotech company.

# ALI TEHRANI


## President, Co-founder and CEO, Zymeworks

Dr. Ali Tehrani is one of the co-founders of Zymeworks and currently serves the President and Chief Executive Officer. Dr. Tehrani has served as a member of our Board of Directors since the Company's inception in September 2003. He has been an integral part of Zymeworks' numerous corporate achievements including raising seed and angel financing and overseeing the technical operations and patent filings.

Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his Ph.D. degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002. Dr. Tehrani has served as a board director for the Student Biotechnology Network and LifeSciences British Columbia, on the MITACS Industrial Advisory Board, and on BIOTECanada's Industrial and Environmental Committee. Currently, he is a member of the board of directors of Creatus Biosciences Inc. and CQDM and a Council Member on British Columbia's Premier's Technology Council.

# 2017 HIGHLIGHTS

Zymeworks licensed the Azymetric™ and EFECT™ platforms to Janssen and was listed on the New York Stock Exchange.



Graphic: Brian Calvert and Neil Klompas



# 18

## Judging Panel

**Karen Bernstein**

**CO-FOUNDER AND CHAIRMAN**  
BioCentury Inc.

**Dennis Purcell**

**FOUNDER AND SENIOR ADVISOR**  
Aisling Capital

**Cecilia Gonzalo**

**MANAGING DIRECTOR**  
Vatera Healthcare Partners

**Melinda Richter**

**GLOBAL HEAD**  
Johnson & Johnson Innovation, JLABS

**Carl Gordon**

**PARTNER AND CO-HEAD OF GLOBAL EQUITY**  
OrbiMed Advisors

**Avik Roy**

**OPINION EDITOR; PRESIDENT**  
Forbes; The Foundation for Research and Equal Opportunity

**Mayukh Sukhatme**

**CHIEF BUSINESS OFFICER**  
Roivant Sciences



## Karen Bernstein

---

Karen is co-founder and chairman of BioCentury Inc. and was Editor-in-Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is focused on developing drugs for orphan diseases of the brain, and at Achaogen Inc., which is developing drugs to treat multi-drug resistant gram-negative infections. She is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she served for many years as a member of the Brandeis University Science Advisory Council. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community. In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, she was named as one of the 100 Women of Influence in Silicon Valley by the Silicon Valley Business Journal. In 2015, Scientific American named Karen as one of The WorldVIEW 100 most influential people in biotech today. In 2016, she was named Commentator of the Year by the European Mediscience Awards.



## Cecilia Gonzalo

---

Cecilia Gonzalo is responsible for sourcing new investments and overseeing Vatera Healthcare Partners' existing investments in biopharmaceuticals. She has over 20 years of investment and finance experience, with over 15 years in the healthcare sector. Combining her background in biochemical sciences and finance, Cecilia has invested in a number of innovative healthcare companies with the goal of bringing value-added products and services to market while generating attractive investment returns. Over the years, Cecilia has effectively identified attractive investment opportunities and partnered with talented management teams to create long-standing value while serving patients' unmet needs.

Cecilia joined the firm in 2015. Before that, she was a Managing Director at Essex Woodlands, a healthcare-focused growth equity firm, where she worked on investing across the healthcare sector in the U.S., Latin America and Europe. Prior to Essex Woodlands, Cecilia spent 12 years at Warburg Pincus LLC, a global private equity firm, where she was a Managing Director focusing on healthcare investments. Before Warburg Pincus LLC, she was an Analyst at Goldman, Sachs & Co. both in the Investment Banking Division and Principal Investment Area. Cecilia is currently a board member and a Co-President of the Harvard Business School Healthcare Alumni Association. Cecilia holds an AB in Biochemical Sciences from Harvard College and an MBA from Harvard Business School.



## Carl Gordon

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last five years (2014 to 2018) Forbes® Magazine named Mr. Gordon one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).



## Dennis Purcell

---

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over \$10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.

Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine -Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.

Mr. Purcell received his M.B.A. from Harvard Business School and his B.S. in Accounting from the University of Delaware.



## Melinda Richter

---

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson's sectors: consumer, medical device and pharmaceuticals.

Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set out to create a better model, which now forms the basis for JLABS' operational infrastructure. Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also initiated, raised capital and secured large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and a MBA from INSEAD in France. Melinda is an active board member and Treasurer of the California Life Sciences Association (CLSA).



## Avik Roy

---

Avik Roy is one of North America's leading experts on healthcare policy. His reform proposal, *Transcending Obamacare: A Patient-Centered Plan for Near-Universal Coverage and Permanent Fiscal Solvency*, is one of the plans most influential in Washington as Republicans debate how to replace the Affordable Care Act.

Mr. Roy has advised a number of the 2016 presidential candidates on healthcare and other areas of public policy, including Marco Rubio and Rick Perry. In 2012, Mr. Roy served as healthcare policy advisor to Mitt Romney; in that role, he helped develop Romney's agenda on healthcare and entitlement reform for the 2012 presidential campaign. He also served on Romney's presidential transition team, in which capacity he was responsible for recommending candidates for the major healthcare positions in the federal government, including at HHS, CMS, and the FDA.

Mr. Roy is the President of the Foundation for Research on Equal Opportunity (FREOPP.org) and the Managing Partner at Roy Healthcare Research, LLC, which provides proprietary healthcare investment and policy research to institutional investors and stakeholders. Roy's work has been praised widely on both the right and the left. *National Review* has called him one of America's "sharpest policy minds," while the *New York Times'* Paul Krugman described him as man of "personal and moral courage."

Prior to his career in healthcare policy, Mr. Roy spent a dozen years on the Wall Street buy side as a health care analyst and portfolio manager, at institutions such as Bain Capital and J.P. Morgan.



## Mayukh Sukhatme

Dr. Sukhatme currently serves as President of Roivant Pharma, a business unit of Roivant Sciences. Roivant Pharma is focused on end-to-end biopharmaceutical company creation, launch, and oversight. Roivant Pharma companies include Myovant, Axovant, Arbutus, Urovant, Enzyvant, Dermavant, Genevant, Metavant, Immunovant, and Altavant. From November 2016 to June 2018, Dr. Sukhatme served as Roivant's Chief Business Officer and from April 2015 to November 2016 as Senior Vice President, Business Development. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned an M.D. from Harvard Medical School and a B.S. in Biology and a B.S. in Literature from the Massachusetts Institute of Technology.

# 2018 Table Sponsors

A special thank you to  
all our sponsors who  
share our vision for the  
Canadian healthcare  
sector





2018

# Block Ticket Sponsors

# Bloom Burton & Co. Healthcare Investor Conference

Metro Toronto Convention Centre

April 30 - May 1 2019



bloom burton & co

[/accelerating returns in healthcare](#)



BLOOM BURTON  
AWARD GALA

THURSDAY, SEPTEMBER 27, 2018

FOUR SEASONS HOTEL

TORONTO, ONTARIO